The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 3, Issue 4, Pages 171-184
Publisher
SAGE Publications
Online
2011-06-03
DOI
10.1177/1758834011408636
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors
- (2017) L. H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor-Dependent Fashion to Suppress Carcinoma Growth
- (2010) Y.-W. Zhang et al. CANCER RESEARCH
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Novel Oncogenic Mutations ofCBLin Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism
- (2010) Margret S. Fernandes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
- (2010) Yi-Hung Carol Tan et al. PLoS One
- Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
- (2009) F. H. Grand et al. BLOOD
- The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
- (2009) T. Y. Seiwert et al. CANCER RESEARCH
- Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
- (2009) S. Krishnaswamy et al. CLINICAL CANCER RESEARCH
- Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
- (2009) Gretchen M. Schroeder et al. JOURNAL OF MEDICINAL CHEMISTRY
- PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription
- (2009) Rajani Kanteti et al. LABORATORY INVESTIGATION
- Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications
- (2008) Margret S. Rodrigues et al. ANTIOXIDANTS & REDOX SIGNALING
- High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
- (2008) M. M. Loriaux et al. BLOOD
- MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
- (2008) H. Jin et al. CANCER RESEARCH
- Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
- (2008) R. Jagadeeswaran et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started